Skip to main content

Table 2 Targeting ferroptosis in breast cancer- currently available pharmaceutical agents

From: Targeting ferroptosis in breast cancer

Drug

Origin

Improvement/function

Phenomenon and characteristics

Year

Reference

Ironomycin

Salinomycin

Accumulating and sequestering iron in lysosomes

Iron overload and reactive oxygen species overgeneration

2017

[51]

CSO-SS-Cy7-Hex/SPION/Srfn

Sorafenib, iron

Combined iron and sorafenib

Iron overload, intracellular depletion of glutathione and reactive oxygen species overgeneration

2019

[106]

Erastin@FA-exo

Erastin

TNBC targetting, increased biocompatibility

Intracellular depletion of glutathione and reactive oxygen species overgeneration

2019

[107]

MnO2@HMCu2-xS nanocomposites

Mn2+, rapamycin

Combined Fenton-like reaction by Mn2+ and autophagy by rapamycin

Iron overload and reactive oxygen species overgeneration

2019

[108]

Drug-organics-inorganics self-assembled nanosystem

Doxorubicin, iron, tannic acid

Combined chemotherapy, ferroptosis and superoxide dismutase (SOD)-like reaction

Iron overload and reactive oxygen species overgeneration

2019

[109]

Nanoparticle ferritin-bound erastin and rapamycin

Erastin, rapamycin

Combined ferroptosis and autophagy

GPX4 downregulation and lipid peroxidation accumulation

2019

[110]

Ascorbate plus nanocarrier loading Fe3+ and RSL3

Ascorbate, iron, RSL3

Increased specificity to target cancer cells by ascorbate

Iron overload, inhibition of GPX4 and reactive oxygen species overgeneration

2019

[111]